BRIEF published on 11/12/2025 at 08:05, 2 months 23 days ago Pentixapharm publie ses résultats financiers pour les 9 premiers mois de 2025 Perte Financière Revenu Pentixapharm Résultats À 9 Mois Ajustement Des Directives
PRESS RELEASE published on 11/12/2025 at 08:00, 2 months 23 days ago Pentixapharm Publishes 9-Month Figures for 2025 Pentixapharm announces 9-month figures for 2025, reports €12.7 million loss. Adjusted guidance projects approximately €18 million loss for the fiscal year. New financial statements available on website Financial Statements 2025 Loss 9-month Figures Pentixapharm
BRIEF published on 11/10/2025 at 08:05, 2 months 25 days ago Pentixapharm publiera ses résultats financiers pour le troisième trimestre et les neuf premiers mois de 2025. Résultats Financiers Biotechnologie Oncologie Produits Radiopharmaceutiques Pentixapharm
BRIEF published on 11/10/2025 at 08:05, 2 months 25 days ago Pentixapharm to Release Financial Results for Q3 and Nine Months of 2025 Financial Results Oncology Biotech Radiopharmaceuticals Pentixapharm
PRESS RELEASE published on 11/10/2025 at 08:00, 2 months 25 days ago Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025 Pentixapharm Holding AG to release Third Quarter and First Nine Months 2025 Financial Results on November 12, 2025. Conference call and webcast to follow Financial Results Conference Call Berlin Radiopharmaceuticals Pentixapharm
BRIEF published on 11/06/2025 at 20:00, 2 months 28 days ago Pentixapharm Holding AG réduit ses prévisions de pertes pour 2025 Développement Clinique Prévisions Financières Réduction Des Coûts Industrie Biotechnologique Optimisation Stratégique
BRIEF published on 11/06/2025 at 20:00, 2 months 28 days ago Pentixapharm Holding AG Reduces Projected Loss for 2025 Biotech Industry Clinical Development Cost Reduction Financial Forecast Strategic Optimization
PRESS RELEASE published on 11/06/2025 at 19:55, 2 months 28 days ago EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for financial year 2025 Pentixapharm Holding AG significantly reduces projected loss for financial year 2025 due to clinical development program realignment Clinical Development Realignment Pentixapharm Financial Year 2025 Projected Loss
BRIEF published on 10/23/2025 at 22:17, 3 months 12 days ago Pentixapharm recentre sa stratégie et réduit ses coûts Développement Clinique Réduction Des Coûts Produits Radiopharmaceutiques Réduction Des Effectifs Stratégie Biotechnologique
BRIEF published on 10/23/2025 at 22:17, 3 months 12 days ago Pentixapharm Refocuses Strategy and Reduces Costs Clinical Development Cost Reduction Radiopharmaceuticals Workforce Reduction Biotech Strategy
Published on 02/05/2026 at 12:30, 12 minutes ago Relevant Gold Appoints Larry Taddei to Board of Directors and Mal Karwowska as Strategic Advisor
Published on 02/05/2026 at 12:30, 12 minutes ago Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation Pipeline
Published on 02/05/2026 at 12:00, 42 minutes ago Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026
Published on 02/05/2026 at 09:05, 3 hours 37 minutes ago BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
Published on 02/05/2026 at 01:35, 11 hours 7 minutes ago Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 11:47, 55 minutes ago Worthington Steel Announces Start of Acceptance Period for All-Cash Tender Offer of €11.00 per Share to Shareholders of Kloeckner & Co SE
Published on 02/05/2026 at 11:45, 56 minutes ago EQS-WpÜG: Takeover Offer / Target company: Klöckner & Co SE; Bidder: Worthington Steel GmbH
Published on 02/05/2026 at 11:30, 1 hour 12 minutes ago Linde Reports Full-Year and Fourth-Quarter 2025 Results (Earnings Release Tables Attached)
Published on 02/05/2026 at 11:30, 1 hour 12 minutes ago Déclaration nombre d'actions et droits de vote - 05.02.2026
Published on 02/05/2026 at 11:30, 1 hour 12 minutes ago Disclosure of shares outstanding and voting rights - 05.02.2026
Published on 02/04/2026 at 18:04, 18 hours 37 minutes ago Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 18 hours 37 minutes ago Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 18 hours 57 minutes ago Information concerning the total number of voting rights and shares 2026 01 31
